“Modest” Survival Gains Seen for De Novo Metastatic Cancers in Last 30 Years
Patients with de novo metastatic cancer have seen modest improvements in survival over the last 3 decades, according to researchers.
Patients with de novo metastatic cancer have seen modest improvements in survival over the last 3 decades, according to researchers.
The approvals were based on data from the LIBRETTO-001 trial.
An analysis of data from SEER-Medicare database compared end-of-life care, including hospitalizations and use of hospice, between patients with solid tumors and hematologic malignancies.
These are the first set of recommendations on the use of tumor multigene NGS profiling in daily practice issued by a scientific society for patients with metastatic cancer.
Reactive hyperemia peripheral arterial tonometry index ≤2.0 predicted incidence of solid-tumor cancer.
Using fictional patient profiles and a questionnaire on recommendation procedures, researchers were able to demonstrate a need for standardized tumor board interpretation and recommendation processes worldwide.
Using a comparator group, researchers sought to determine the impact of a diagnosis of solid tumor on outcomes among postsurgical ICU admissions in patients with cancer vs those without cancer.
Tazemetostat demonstrated preclinical activity against EZH2-mutant non-Hodgkin lymphomas.
[Breast Cancer: Targets and Therapy] A review of studies investigating the efficacy of buparlisib monotherapy and in combination with various other anticancer agents in the treatment of breast cancer and other solid tumors.
Study results demonstrate that statins have antitumor activity in various solid-tumor cancers and leukemia; however, experts offer these caveats on using them to treat cancer — at least for now.